Industry Experts

Lars Linden is VP, Therapeutic Antibodies at Bayer and drives research activities in antibodies, multi-specifics, therapeutic proteins and AAV biology. Lars joined Bayer in 2007 and has held various positions as Scientist, Group Leader and Director in the Biologics Organisation, responsible for the production of antibody-based research compounds and tools for biologics projects in Bayer's early research pipeline, and overseeing the developability assessment of clinical candidates. Lars also has a track record of successfully leading preclinical research portfolio projects in oncology (ADCs and IO) and ophthalmology. Prior to this, he worked in a small biotech environment on structural biology of GPCRs and ion channels. Lars holds a PhD in Structural Biology from the Max Planck Institute of Biochemistry/Technical University of Munich.